FDA Panel Okays Keytruda’s Hepatocellular Carcinoma Indication, But Splits On Opdivo

 
• By Brenda Sandburg
Opposite results
FDA advisory panel reaches opposite conclusions on Keytruda, Opdivo HCC indication • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers